Skip to main content
MenuSearch & Directory

Cancer Clinical Trials

Saint Louis University School of Medicine faculty in hematology, oncology, and cellular therapy are committed to leadership in clinical research programs. Also as faculty of SSM Health Saint Louis University Hospital, our staff regularly conducts clinical trials of new medicines and technologies. The following studies are now seeking participants.


Phase 2 Study of MK-2140 in Relapsed Refractory Diffuse Large B Cell Lymphoma 

Merck/MK2140-004 - Dr. Sagun Goyal

A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Aberrant Hematopoiesis; R01 Title: The Roles of AML1-ETO and E-Proteins in t(8;21) Acute Myeloid Leukemia

Dr. Jinsong Zhang

A study to examine acute myeloid leukemia (AML) among patients seen through the Bone Marrow Transplant Center/Team at SSM Health Saint Louis University Hospital.

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

ECOG-ACRIN/ EA4151 - Dr. Sagun Goyal

A randomized phase III trial of consolidation with autologous hematopoietic cell transplantation followed by maintenance rituximab vs. maintenance rituximab alone for patients with mantle cell lymphoma in minimal residual disease-negative first complete remission.

Randomized, Open-Label, Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Best Available Therapy in Subjects With Relapsed/Refractory Myelofibrosis (TRANSFORM-2/M20-178)

AbbVie/ M20-178 - Dr. Sagun Goyal

Navitoclax is an investigational drug (not yet approved) being developed for the treatment of Myelofibrosis (MF). The study has two arms - A and B. In Arm A, participants will receive navitoclax in combination with ruxolitinib. In Arm B, participants will receive the best available therapy (BAT) for MF. Adult participants diagnosed with relapsed/refractory (R/R) MF will be enrolled.

A Longitudinal Observational Study of the Natural History and Management of Patients With Hepatocellular Carcinoma.

Target PharmaSolutions/TargetHCC - Dr. John Richart

TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.

Immunological Response to Infection, Vaccination, and Disease.

Dr. James Brien

A study to determine immune response to the SARS-CoV-2 vaccine in patients who have blood cancers who will be or have been treated with bone marrow transplant. 

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer

AstraZeneca/PACIFIC4 - Dr. Jeevin Shahi

This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC.

Just-in-Time: Evaluating a Decision-based Algorithm for Plerixafor Usage in Stem Cell Mobilization in an Outpatient Transplant Center.

Dr. Alexander Babic

A study to evaluate stem cell collection times for patients seen at the Outpatient Bone Marrow Transplant Center at SSM Health Saint Louis University Hospital.

Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia (GS-US 546-5857)

Gilead Sciences/Enhance-2 - Dr. Nabeel Rajeh (Temporary hold on enrollment)

The primary objective of this study is to compare the efficacy of magrolimab + azacitidine versus venetoclax + azacitidine in adults with previously untreated TP53 mutant acute myeloid leukemia (AML) who are appropriate for non-intensive therapy as measured by overall survival (OS).

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy (GS-US-590-6154)

Gilead Sciences/Enhance-3 - Dr. Nabeel Rajeh (Temporary hold on enrollment)

The primary objectives of this study are to compare the efficacy of magrolimab + venetoclax + azacitidine versus placebo + venetoclax + azacitidine in participants with previously untreated acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.

Reaching Rural Cancer Survivors who Smoke Using Test-Based Cessation Interventions

Alliance/A211901 - Dr. John Dombrowski

This phase III trial compares the effect of text-based cessation intervention to a manual in helping rural cancer patients who smoke to quit. Text-based scheduled gradual reduction may reduce the frequency of cigarette use to zero and may be effective in quitting smoking.

A Phase 1b/3 Double-blind Randomized, Active-controlled, 3-stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination With Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma

Epizyme/EZH-302 - Dr. Nabeel Rajeh

This is a multicenter, double-blind, active-controlled, randomized, 3-stage, biomarker enrichment design featuring early futility stopping and sample-size re-estimation with safety run-in designed to evaluate the efficacy and safety of tazemetostat in combination with lenalidomide and rituximab (R2) in subjects with relapsed or refractory (R/R) follicular lymphoma (FL), who have completed at least one prior systemic chemotherapy, immunotherapy, or chemoimmunotherapy.

Randomized Phase II/III Trial Of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection For Early-Stage Oral Cavity Cancer

NRG/HN006 - Dr. Sean Massa

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy surgery is a procedure that removes a smaller number of lymph nodes from your neck because it uses an imaging agent to see which lymph nodes are most likely to have cancer. Standard neck dissection, such as elective neck dissection, removes many of the lymph nodes in your neck. Using sentinel lymph node biopsy surgery may work better in treating patients with early-stage oral cavity cancer compared to standard elective neck dissection.

A Multicenter, Open-label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177 Lu-PSMA-I&T vs. Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

Curium/Eclipse - Dr. Razi Muzaffar

A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

64Cu-SAR-BBN Positron Emission Tomorgraphy: A Phase 2 Study of Participants with PSMA-negative Biochemical Recurrence of Prostate Cancer

Clarity Pharmeceuticals, Ltd/SABRE - Dr. Medhat Osman

The aim of this study is to determine the safety and efficacy of 64Cu-SAR-BBN and determine the ability of 64Cu-SAR-BBN Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with PSMA-negative biochemical recurrence of prostate cancer following definitive therapy.

A Phase I/1Ia, First-in-Human, Multicenter Dose Escalation and Dose Expansion Study of {203 212Pb} VMT01 Receptor-targeted, Image-guided Alpha-particle Therapy in Patients with Previously Treated Unresectable or Metastatic Melanoma

Viewpoint Molecular Targeting - Dr. Medhat Osman

In this first-in-human, phase I/IIa study, the safety and efficacy of [212Pb]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated in patients with unresectable and metastatic melanoma.

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

NRG - Dr. Jeevin Shahi

This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient's cancer aggressiveness.